Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175157 | 0.90 | EGFR (0.53) | EGFRERBB2LCKERBB4FLT1 | |
| SCHEMBL5081050 | 0.90 | ERBB2 (0.52) | EGFRERBB2ERBB4ERBB3 | |
| SCHEMBL4797355 | 0.88 | EGFR (0.60) | EGFRERBB2ERBB4ERBB3 | |
| SCHEMBL6487993 | 0.88 | EGFR (0.51) | EGFRERBB2LCKERBB4ERBB3 | |
| SCHEMBL5077437 | 0.87 | EGFR (0.51) | EGFRERBB2LCKERBB4ERBB3 | |
| SCHEMBL6174356 | 0.87 | EGFR (0.63) | EGFRERBB2LCKERBB4ERBB3 | |
| SCHEMBL6175165 | 0.86 | EGFR (0.55) | EGFRERBB2ERBB4ERBB3FLT1 | |
| SCHEMBL6189113 | 0.86 | ERBB2 (0.51) | EGFRERBB2LCKERBB4FLT1 | |
| SCHEMBL6175138 | 0.86 | ERBB2 (0.49) | EGFRERBB2LCKERBB4FLT1 | |
| SCHEMBL6486733 | 0.86 | EGFR (0.51) | EGFRERBB2LCKERBB4ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | FRIZER INC. | 2008-08-14 | — | — | US | disclosed |
| US-20050101618-A1 | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | PFIZER INC | 2005-05-12 | — | — | US | disclosed |
| US-6890924-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101618-A1 | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885LCK 28/4885 |
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885LCK 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.